Overview

* Xencor ( XNCR ) Q2 revenue rises to $43.6 mln, beating analyst expectations, per LSEG data

* Adjusted EPS loss of $0.41 beats estimates, per LSEG data

* Net loss narrows to $30.8 mln from $67.3 mln a year ago

Outlook

* Xencor ( XNCR ) expects to end 2025 with $555-585 mln in cash

* Company anticipates funding operations into 2028

Result Drivers

* MILESTONE PAYMENTS - Revenue increase driven by $25 mln milestone payment from Incyte for Monjuvi approval

* ROYALTY REVENUE - Non-cash royalty revenue from Alexion and Incyte contributed to Q2 revenue

* R&D SPENDING - Stable R&D expenses reflect increased spending on XmAb819, XmAb541, and XmAb657, offset by reduced costs from terminated programs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $43.60 $21.40

Revenue mln mln (11

Analysts

)

Q2 EPS Beat -$0.41 -$0.72

(11

Analysts

)

Q2 Net -$30.82

Income mln

Q2 $76.78

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Xencor Inc ( XNCR ) is $31.00, about 74.4% above its August 5 closing price of $7.95

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)